Endocare Rejects Unsolicited Proposal From HealthTronics
August 13 2008 - 5:00AM
PR Newswire (US)
IRVINE, Calif., Aug. 13 /PRNewswire-FirstCall/ -- Endocare, Inc.
(NASDAQ:ENDO) announced today that its Board of Directors has
unanimously rejected the unsolicited proposal from HealthTronics,
Inc. (NASDAQ:HTRN) to purchase all of the outstanding shares of
Endocare for $2.28 per share. After careful evaluation, the Board
determined that the proposal is inadequate and not in the best
interests of Endocare's stockholders. About Endocare Endocare, Inc.
-- http://www.endocare.com/ -- is an innovative medical device
company focused on the development of minimally invasive
technologies for tissue and tumor ablation. Endocare has initially
concentrated on developing technologies for the treatment of
prostate cancer and believes that its proprietary technologies have
broad applications across a number of markets, including the
ablation of tumors in the kidney, lung and liver and palliative
intervention (treatment of pain associated with metastases).
Investor Contact: Media Contact: For Additional Matt Clawson Len
Hall Information: Allen & Caron, Inc. Allen & Caron, Inc.
Craig T. Davenport, CEO (949) 474-4300 (949) 474-4300 Michael R.
Rodriguez, CFO Endocare, Inc. http://www.allencaron.com/
http://www.allencaron.com/ (949) 450-5400 http://www.endocare.com/
DATASOURCE: Endocare, Inc. CONTACT: Investor Contact, Matt Clawson,
, or Len Hall, , both of Allen & Caron, Inc., +1-949-474-4300,
both for Endocare, Inc.; or For Additional Information, Craig T.
Davenport, CEO, or Michael R. Rodriguez, CFO, both of Endocare,
Inc., +1-949-450-5400 Web site: http://www.endocare.com/
Copyright
Htetf (MM) (NASDAQ:HTRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Htetf (MM) (NASDAQ:HTRN)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Htetf (MM) (NASDAQ): 0 recent articles
More Healthtronics (MM) News Articles